Trinucleotide cap analogs, preparation and uses thereof

Patent metadata

Field	Value
Publication number	US-12385039-B2
Application number	US-202117364956-A
Country	US
Kind code	B2
Filing date	Jul 1, 2021
Priority date	Jul 2, 2020
Publication date	Aug 12, 2025
Grant date	Aug 12, 2025

Abstract

This specification generally relates to trinucleotide RNA cap analogs, methods of use thereof, and kits comprising same. In particular, the trinucleotide cap analogs provided herein permit ready detection and/or isolation of capped RNA transcripts in vitro and translation of capped mRNAs in vivo.

First claim

What is claimed is:

1. A trinucleotide cap analog of Formula (I)

wherein
B 3 is chosen from —OH, halogen, dyes, —OR 1 ,
wherein R 1 is chosen from propargyl, tert-butyldimethylsilyl, and a methylene bridge with the 4′C;
B 4 is chosen from —OH, dyes, and —OR 2 , wherein R 2 is chosen from propargyl and tert-butyldimethylsilyl;
or R 1 joins with R 2 such that B 3 and B 4 form -2′,3′-O-isopropylidine;

on the condition that B 3 and B 4 cannot both be —OH
X is chosen from —H and —CH 3 ;
B 1 and B 2 are each independently chosen from adenine, guanine, cytosine, and uracil;
R is chosen from H, a linker-bound cell-penetrating peptide, a linker-bound cell-penetrating peptide covalently linked to a dye, and a linker-bound dye,
wherein the cell-penetrating peptide is selected from the group consisting of SEQ ID NOs: 1-10.

2. A composition comprising RNA having a trinucleotide cap analog of claim 1 , covalently bonded thereto.

3. The composition of claim 2 , further comprising at least one RNA delivery agent.

4. The composition of claim 3 , wherein the at least one RNA delivery agent comprises at least one cationic lipid.

5. A kit comprising:
a trinucleotide cap analog claim 1 ;
nucleotide triphosphate molecules; and
an RNA polymerase.

6. The trinucleotide cap analog of claim 1 , wherein B 3 is —OR 1 , and R 1 forms a methylene bridge with the 4′C such that the trinucleotide cap analog is of Formula (II):

7. The trinucleotide cap analog of claim 1 , wherein each dye is independently chosen from azobenzene dyes, naphthalene containing dyes, cyanine dyes, rhodamine dyes, coumarin, and pyrene dyes.

8. The trinucleotide cap analog of claim 1 , wherein
B 3 is —OR 1 and B 4 is —OR 2 wherein R 1 joins with R 2 such that B 3 and B 4 form -2′,3′-O-isopropylidene;
X is —CH 3 ; and
R is H.

9. The trinucleotide cap analog of claim 1 , wherein
B 3 is chosen from —OR 1 wherein R 1 is chosen from propargyl and tert-butyldimethylsilyl;
B 4 is —OH; and
R is H.

10. The composition of claim 4 , wherein the at least one RNA delivery agent comprises at least one cationic lipid and at least one neutral lipid.

11. The composition of claim 10 , wherein the at least one neutral lipid is a phospholipid.

12. The composition of claim 10 , wherein the at least one neutral lipid is a sterol.

13. The composition of claim 2 , wherein the RNA comprises one or more modified nucleotides.

14. The composition of claim 13 , wherein the one or more modified nucleotides is selected from the group consisting of pseudouridine (ψ) triphosphate, 1methylpseudouridine (m 1 ψ) triphosphate, 5-methoxyuridine (mo 5 U) triphosphate, 5-methylcytidine (m 5 C) triphosphate, α-thio-guanosine triphosphate, α-thio-adenosine triphosphate, and any combination thereof.

15. The trinucleotide cap analog of claim 1 , wherein B 4 is propargyl.

16. The trinucleotide cap analog of claim 15 , having the structure

Assignees

• Life Technologies Corp

Inventors

• Kore Anilkumar
• Annamalai Senthilvelan
• Muthian Shanmugasundaram
• Potter Robert
• Vonderfecht Tyson

Classifications

• C12Y207/07006

  DNA-directed RNA polymerase (2.7.7.6) · CPC title

• C12N2320/32

  Special delivery means, e.g. tissue-specific · CPC title

• C12N2310/3519

  Fusion with another nucleic acid · CPC title

• C12N2310/3231

  having an additional ring, e.g. LNA, ENA · CPC title

• C12N9/1247

  DNA-directed RNA polymerase (2.7.7.6) · CPC title